Plasmin inhibitors in different fibrinolytic treatment patterns.
The variations of different antiplasmins were studied in a group of patients suffering from thromboembolic conditions and receiving three different regimens of thrombolytic treatment with streptokinase and urokinase. The evaluation of the antiproteases was carried out by chromogenic substrate and radial immunodiffusion. The different administration patterns of the fibrinolytic agents were followed by a clear drop in fast antiplasmin and alpha 2-macroglobulin, while alpha 1-antitrypsin was increased. Antithrombin-III activity was reduced while its protein rose in the intermittent treatment with streptokinase. In the conventional treatment with streptokinase, both the activity and the protein of antithrombin-III increased. With urokinase both the protein and the activity of antithrombin-III were slightly reduced. Plasminogen and fibrinogen decreased in the different regimens of thrombolytic treatment, being more evident in continuous administration of streptokinase.
D000990:Antithrombin III / Q000378:metabolism; D010450:Endopeptidases / Q000627:therapeutic use*; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D010958:Plasminogen / Q000378:metabolism; D013299:Streptodornase and Streptokinase / Q000627:therapeutic use*; D013923:Thromboembolism / Q000097:blood* / Q000188:drug therapy; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*; D000515:alpha 1-Antitrypsin / Q000378:metabolism; D000979:alpha-2-Antiplasmin / Q000378:metabolism*; D000511:alpha-Macroglobulins / Q000378:metabolism
D000515:alpha 1-Antitrypsin; D000979:alpha-2-Antiplasmin; D000511:alpha-Macroglobulins; D000990:Antithrombin III; D005340:Fibrinogen; D010958:Plasminogen; D013299:Streptodornase and Streptokinase; D010450:Endopeptidases; D014568:Urokinase-Type Plasminogen Activator